Pritelivir - AiCuris

Drug Profile

Pritelivir - AiCuris

Alternative Names: AIC-316; BAY 57-1293

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer AiCuris
  • Class Amides; Antivirals; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Phase II Herpes labialis; Herpes simplex virus infections; Herpes simplex virus type 2 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(In volunteers) in Germany (PO)
  • 13 Oct 2017 AiCuris Anti-infective Cures and TKL Research completes the phase II LipP1 trial for Herpes labialis (In treatment-experienced) in USA (Topical) (NCT02871492)
  • 01 Aug 2017 Pritelivir receives Fast Track designation for Herpes simplex virus infections [PO,Tablet] (Treatment-resistant) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top